A. Van-sighem, S. Danner, A. Ghani, L. Gras, R. Anderson et al., Determinants of survival following HIV-1 seroconversion after the introduction of HAART Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-Infected individuals, CASCADE Collaboration, pp.1267-74212, 2003.

G. Chêne, J. Sterne, M. May, D. Costagliola, B. Ledergerber et al., Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies, Lancet, vol.362, pp.679-86, 2003.

A. Study and G. , HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long term combination antiretroviral therapy reach same mortality rates as the general population, J Acquir Immune Defic Syndr, vol.46, pp.72-79, 2007.

Y. Gazzard, B. Clumeck, N. Losso, M. Lundgren, and J. , Recommandations du groupe d'experts Available from When should antiretroviral therapy for HIV be started?, BMJ, vol.334, pp.76-84, 2006.

D. The and . Group, Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, vol.356, pp.1723-1758, 2007.